A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
8d agoen
From the article
Conditions : Breast Cancer Interventions : Drug: BL-M07D1; Drug: DS-8201 Sponsors : Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer
OncoDaily·9h ago
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
doi.org·1d ago
Development of LRRC15-binding disulfide-constrained peptides for PET imaging of cancer-associated fibroblasts
doi.org·15h ago
Gemma-Based AI Model Identifies Potential Cancer Therapy Pathway Through Conditional Immune Amplification
Researchers used a new 27 billion parameter foundation model called C2S-Scale 27B, built on Google's Gemma family of open models, to discove
blog.google·8mo agoNICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
GSK·17y ago
Samjin Pharm Launches Breast Cancer Treatment Fulveserd
Seoul Economic Daily·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.